Dapagliflozin

What is Dapagliflozin?

Dapagliflozin is a selective sodium-glucose cotransporter-2 (SGLT2) inhibitor approved for the treatment of type 2 diabetes mellitus and heart failure with reduced ejection fraction. It belongs to the ATC classification A10, which encompasses all antidiabetic agents. Dapagliflozin was first approved by the FDA in January 2014 and has since become a cornerstone medication in diabetes and cardiovascular management worldwide.

The drug represents a novel class of oral antidiabetic agents that work through a unique mechanism distinct from traditional diabetes medications. Dapagliflozin is manufactured by AstraZeneca and is marketed under the brand name Farxiga for heart failure indications and Forxiga for diabetes management. The medication has demonstrated significant benefits in reducing blood glucose levels, promoting weight loss, and improving cardiovascular outcomes in clinical trials.

As an SGLT2 inhibitor, Dapagliflozin has expanded the therapeutic options available to patients with metabolic disorders and heart disease. Its mechanism and clinical benefits have made it a preferred choice for many healthcare providers, particularly in patients with concurrent type 2 diabetes and cardiovascular disease or those with heart failure.

⚙️ Mechanism of Action

Dapagliflozin works by selectively inhibiting the sodium-glucose cotransporter-2 (SGLT2) protein located in the proximal convoluted tubule of the nephron. Under normal physiological conditions, SGLT2 reabsorbs filtered glucose from the urine back into the bloodstream, helping to maintain blood glucose levels. By blocking this transporter, Dapagliflozin prevents glucose reabsorption, allowing excess glucose to be excreted through the urine—a process called glycosuria.

• Inhibition of SGLT2 in the kidney's proximal tubule prevents glucose reabsorption and promotes urinary glucose excretion
• Reduction of blood glucose levels occurs independently of pancreatic insulin secretion, making it effective across various stages of type 2 diabetes
• Osmotic diuresis results from increased glucose in the urine, leading to mild diuretic effects and blood pressure reduction
• Improved myocardial energy metabolism and reduced cardiac fibrosis contribute to heart failure benefits
• Activation of AMP-activated protein kinase (AMPK) pathway promotes metabolic improvements and reduces systemic inflammation

🏥 Medical Uses & Indications

Dapagliflozin has demonstrated efficacy in multiple clinical conditions beyond its initial indication as an antidiabetic agent. The medication is now recognized for its cardioprotective and renoprotective properties, expanding its role in comprehensive chronic disease management. Clinical evidence supports its use across diverse patient populations, from those with newly diagnosed diabetes to those with advanced heart failure.

Primary Indications

• Type 2 diabetes mellitus—as monotherapy or in combination with other antidiabetic agents to improve glycemic control
• Heart failure with reduced ejection fraction (HFrEF)—to reduce the risk of cardiovascular death and hospitalization for worsening heart failure
• Chronic kidney disease with or without diabetes—to slow progression of renal disease and reduce albuminuria
• Type 1 diabetes—in combination with insulin therapy in select patients to improve glycemic control
• Diabetic kidney disease—to reduce the progression of albuminuria and decline in glomerular filtration rate
• Cardiovascular risk reduction in patients with type 2 diabetes and established cardiovascular disease

Secondary / Off-label Uses

• Heart failure with preserved ejection fraction (HFpEF)—emerging evidence supports use in this population
• Polycystic ovary syndrome (PCOS)—may improve insulin resistance and metabolic parameters
• Non-alcoholic fatty liver disease (NAFLD)—potential benefit in reducing hepatic steatosis
• Diabetic retinopathy prevention—additional protective effect in patients with diabetes

💊 Dosage & Administration

Dapagliflozin is administered orally as a tablet, typically taken once daily regardless of meals. The standard dosing regimen is straightforward, which improves medication adherence in clinical practice. Dosage adjustments may be necessary based on renal function, patient age, and concurrent medications. It is important that patients follow their prescriber's specific dosing instructions, as individual requirements may vary based on clinical response and tolerability.

Important: Always follow your prescriber's instructions. Dosages vary by patient weight, age, and condition. Renal function assessment is recommended before initiating Dapagliflozin, as the medication's efficacy decreases with significant renal impairment. Patients with an estimated glomerular filtration rate (eGFR) below 20 mL/min/1.73m² should not use Dapagliflozin.

⚠️ Side Effects

Common Side Effects (>10% of patients)

• Urinary tract infections (UTIs)—occurring in approximately 10-15% of patients, though usually mild and self-limiting
• Genital mycotic infections (yeast infections)—more common in women due to increased glucose in urine promoting fungal growth
• Polyuria (excessive urination)—a direct consequence of increased urinary glucose excretion
• Dehydration and thirst—resulting from osmotic diuresis caused by glycosuria
• Headache—reported in 7-12% of patients in clinical trials
• Nasopharyngitis—upper respiratory tract infections occurring at similar rates to placebo in trials

Less Common Side Effects (1-10%)

• Genital necrotic fasciitis (Fournier's gangrene)—rare but serious necrotizing soft tissue infection of the genital area
• Diabetic ketoacidosis (DKA)—uncommon metabolic complication requiring immediate medical attention
• Acute kidney injury—particularly in patients with pre-existing renal disease or volume depletion
• Vulvovaginal pruritus—itching and discomfort associated with genital infections
• Back pain and arthralgia—joint and musculoskeletal complaints in 3-5% of patients

Rare but Serious Side Effects

• Euglycemic diabetic ketoacidosis—metabolic acidosis occurring without markedly elevated blood glucose levels, which can mask the condition and delay diagnosis
• Amputation risk—increased lower limb amputation rates observed in certain patient subgroups, requiring careful foot examination and monitoring
• Pyelonephritis—severe upper urinary tract infection that may occur secondary to SGLT2 inhibitor use

🔄 Drug Interactions

Dapagliflozin has a favorable drug interaction profile compared to many other antidiabetic medications. However, certain combinations warrant careful monitoring or dose adjustment. The medication undergoes minimal hepatic metabolism, reducing the potential for cytochrome P450-mediated interactions. Patients taking multiple medications should inform their healthcare provider to ensure safe concurrent use.

• Diuretics and other blood pressure-lowering medications—increased risk of hypotension, dehydration, and acute kidney injury when combined with Dapagliflozin
• Insulin and insulin secretagogues—concurrent use increases hypoglycemia risk; dose adjustment of these agents may be necessary
• Other SGLT2 inhibitors—should not be used concurrently with Dapagliflozin as there is no additional benefit and increased adverse effects
• NSAIDs and ACE inhibitors—may elevate serum creatinine and reduce renal function when used with Dapagliflozin
• Carbonic anhydrase inhibitors (topiramate, acetazolamide)—increased risk of metabolic acidosis when combined with Dapagliflozin
• Corticosteroids—may counteract the glucose-lowering effects of Dapagliflozin

🚫 Contraindications & Warnings

• Type 1 diabetes mellitus as monotherapy—Dapagliflozin should not be used alone for type 1 diabetes due to increased ketoacidosis risk; insulin is required
• Severe renal impairment (eGFR <20 mL/min/1.73m²)—the medication is ineffective and potentially harmful in advanced kidney disease
• End-stage renal disease or dialysis patients—contraindicated due to lack of efficacy and safety data in this population
• Diabetic ketoacidosis or history of recurrent DKA—increased risk of euglycemic DKA with Dapagliflozin use
• Acute decompensated heart failure requiring inotropic support—may worsen hemodynamic status in acute settings
• Genital necrotic fasciitis (Fournier's gangrene) history—absolute contraindication for Dapagliflozin rechallenge

Medical Disclaimer: This information is for educational purposes only. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. Do not use this information as a substitute for professional medical advice, diagnosis, or treatment.

❓ Frequently Asked Questions

Is Dapagliflozin safe for long-term use?

Yes, Dapagliflozin has demonstrated safety in long-term clinical trials spanning multiple years. The medication has been used clinically for over a decade with an established safety profile. However, patients should maintain regular medical follow-up to monitor kidney function, blood pressure, and for any emerging side effects. Long-term benefits in reducing cardiovascular events and kidney disease progression have been demonstrated in landmark clinical trials.

Can Dapagliflozin be taken with food?

Dapagliflozin can be taken with or without food. The medication may be taken at any time of day, though taking it at the same time each day helps establish a consistent routine and improve adherence. Food does not significantly affect the absorption or efficacy of Dapagliflozin, making it flexible for patient convenience.

What should I do if I miss a dose?

If you miss a dose of Dapagliflozin, take it as soon as you remember, unless it is almost time for your next scheduled dose. In that case, skip the missed dose and resume your regular dosing schedule. Do not double-dose to make up for a missed dose. If you frequently forget doses, consider using a pill organizer, setting phone reminders, or discussing with your pharmacist about medication synchronization strategies.